Oculis Holding AG (OCS) Liabilities and Shareholders Equity (2021 - 2026)
Quarterly Liabilities and Shareholders Equity rose 37.21% to $311.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Mar 2026, up 56.29% year-over-year, with the annual reading at $295.2 million for FY2025, 114.89% up from the prior year.
Oculis Holding AG's Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $311.6 million for Q1 2026.
- Liabilities and Shareholders Equity came in at $311.6 million for Q1 2026, up from $295.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $311.6 million in Q1 2026 to a low of $38.5 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $150.0 million (2023), against an average of $175.0 million.
- Year-over-year, Liabilities and Shareholders Equity tumbled 38.89% in 2022 and then soared 235.12% in 2023.
- Oculis Holding AG's Liabilities and Shareholders Equity stood at $38.5 million in 2022, then skyrocketed by 235.12% to $128.9 million in 2023, then grew by 6.57% to $137.4 million in 2024, then skyrocketed by 114.89% to $295.2 million in 2025, then increased by 5.54% to $311.6 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Liabilities and Shareholders Equity are $311.6 million (Q1 2026), $295.2 million (Q4 2025), and $209.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 311.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 311.58 Mn |
| Dec 31, 2025 | 295.23 Mn |
| Sep 30, 2025 | 209.81 Mn |
| Jun 30, 2025 | 219.38 Mn |
| Mar 31, 2025 | 227.09 Mn |
| Dec 31, 2024 | 137.39 Mn |
| Sep 30, 2024 | 144.98 Mn |
| Jun 30, 2024 | 153.41 Mn |
| Mar 31, 2024 | 113.09 Mn |
| Dec 31, 2023 | 128.92 Mn |
| Sep 30, 2023 | 145.98 Mn |
| Jun 30, 2023 | 149.97 Mn |
| Dec 31, 2022 | 38.47 Mn |
| Dec 31, 2021 | 62.95 Mn |